Cognizant announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has reached over 100,000 users in 84 countries.
The technology platform has become critical to progressing clinical trials as prevailing social distancing norms have significantly curtailed in-person collaboration, Cognizant said in a statement.
Many of the companies utilizing the Shared Investigator Platform are working to accelerate Covid-19 therapies through virtual clinical trial processes.
The Shared Investigator Platform, in use by 7 of the largest biopharmaceutical companies, links clinical trial sponsors and medical professionals by leveraging automation and remote access technology to increase the speed and efficiency of administering drug trials and bringing new therapies to market.
The Cognizant platform, which was launched in 2016 as part of a collaboration between Cognizant and TransCelerate, a consortium of biopharmaceutical organizations, is used at over 19,000 trial-ready sites by medical and life sciences professionals to cut administrative burdens.
A biopharmaceutical company using the platform realized a 50 percent reduction in critical site activation cycle time, based on an internal sponsor benchmark study.
The Covid-19 pandemic has brought the processes of healthcare and life sciences firms to the forefront of global attention as the need to leverage advanced technologies for faster results and better care is paramount, said Srinivas Shankar, global head for Cognizant’s Life Sciences business.
